



The MEKtrix

Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Thursday, October 9, 2025

11:30 AM ET Doors open

11:45 AM – 1:15 PM ET Presentation

Charlotte Convention Center | Room W207ABCD



The MEKtrix

Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Activity Description

In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans for patients with NF1 that reflect current clinical standards and support individualized, longitudinal management.

Target Audience

Neurologists, neuro-oncologists, neurosurgeons, physician associates (PAs), nurse practitioners (NPs), and nurses

Financial Support

This program is supported through an independent educational grant from SpringWorks Therapeutics, Inc.

Faculty

Rebecca Brown
MD, PhD (Moderator)

Lionel Chow
MD, PhD

Kaleb H. Yohay
MD

Renie Moss
Patient Advocate and Caregiver

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making
- Evaluate the use of MEK inhibitors in the management of NF1-associated PNs in pediatric and adult patients, including team-based care to manage adverse events
- Develop evidence-based, interprofessional care plans for patients with NF1 that reflect current clinical standards and support individualized, longitudinal management

The MEKtrix

Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Accreditation



Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

This activity is designated for 1.5 contact hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Oncology Nursing Certification (ONCC) [ILNA]

This activity is designated for 1.5 contact hours. The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

Physician Assistants (AAPA)

Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



RCP Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.



MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Certificate of Participation

This activity was certified for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™].



ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

The MEKtrix

Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Faculty



Rebecca Brown MD, PhD (Moderator)

Associate Professor of Neuro-Oncology
Departments of Neurology, Neurosurgery,
Internal Medicine, and Dermatology
Director of the Neurofibromatosis and
Schwannomatosis Program
The University of Alabama at Birmingham (UAB)
Birmingham, AL

Rebecca Brown, MD, PhD, is Associate Professor of Neuro-Oncology and Director of the Neurofibromatosis (NF) and Schwannomatosis (SWN) Program at The University of Alabama at Birmingham (UAB) and Children's of Alabama. She is appointed in the Department of Neurology with cross-appointments in Neurosurgery, Internal Medicine, and Dermatology. She is a board-certified neuro-oncologist who specializes in NF and SWN genetic nerve tumor syndromes. Dr. Brown earned her PhD from The Institute for Neuroscience at UT Austin in Texas, studying endocrine-disrupting chemicals, and completed a post-doctoral fellowship at the Center for Strategic and Innovative Technologies at UT Austin in human performance. She then went on to earn her MD from UT Southwestern in Dallas, Texas, in 2013. She completed her intern year at East Tennessee State University and in 2017 her neurology residency at Mount Sinai Hospital in New York City, where she was awarded a competitive grant to perform genome editing of the GTPase-activating domain of neurofibromin. Dr. Brown served as a fellow in neuro-oncology from 2017 to 2019 and as an instructor from 2019 to 2020 at Memorial Sloan Kettering Hospital in New York City, where she developed and studied drug effects on malignant peripheral nerve sheath tumor murine xenografts. In January 2021, she accepted a position as Assistant Professor and Director of the all-ages NF and SWN Clinic at Mount Sinai Hospital, where she partnered with dermatologist Dr. Gulati to conduct a Phase I trial of topical diphenylcyclopropenone for cutaneous neurofibroma treatment. Dr. Brown has experience on both sides of the bench, including basic and translational laboratory research and Phase I-III clinical trials. She is an expert in cutaneous neurofibroma and cutaneous plexiform neurofibroma resections with the goal of reducing incidence of recurrence, avoiding the need for skin grafts, and minimizing scarring. Her research focus is in developing treatments for plexiform and cutaneous neurofibromas.

The MEKtrix

Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Faculty



Lionel Chow MD, PhD

Associate Professor
Dayton Children's Hospital
Boonshoft School of Medicine
Wright State University
Dayton, OH

Lionel Chow, MD, PhD, received his medical training and doctorate at McGill University in Montreal, Canada, where his research focused on the role of tyrosine protein kinases in T-cell activation. He completed his pediatric residency and fellowship in pediatric hematology and oncology at The Hospital for Sick Children in Toronto, Canada. He then moved to St. Jude Children's Research Hospital in Memphis, Tennessee, where his research concentrated on developing animal models of high-grade astrocytoma. Dr. Chow also completed a fellowship in pediatric neuro-oncology at St. Jude. He then joined the faculty at Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio as a pediatric neuro-oncologist as well as conducted research on high-grade astrocytoma and angiosarcoma. Dr. Chow has been an attending hematologist and oncologist at Dayton Children's Hospital in Dayton, Ohio, since 2018. In addition to providing care for pediatric patients with a diverse array of hematologic and oncologic disorders, he anchors a group of providers who deliver multidisciplinary care to children and young adults with brain tumors. He also focuses on the oncologic management of patients with neurocutaneous syndromes. Dr. Chow leads a research program that investigates various aggressive pediatric brain tumors and develops unique patient-derived xenograft models of these tumors in order to uncover novel treatments.

The MEKtrix

Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Faculty



Kaleb H. Yohay MD

Director, Division of Child Neurology
Director, Comprehensive Neurofibromatosis Center
Professor of Neurology and Pediatrics
NYU Langone Grossman School of Medicine
New York, NY

Kaleb H. Yohay, MD, is a Professor of Neurology and Pediatrics at NYU Langone Health and the NYU Grossman School of Medicine. He received his medical degree from the University of Vermont in 1993 and completed residency in pediatrics and neurology at Johns Hopkins Hospital in Baltimore, Maryland. During his tenure at Johns Hopkins, he established and directed the Johns Hopkins Neurofibromatosis Center. In 2007 he joined the faculty at Weill Cornell Medical Center in New York City and served as attending physician at New York Presbyterian and Memorial Sloan Kettering Cancer Center. In 2014, Dr. Yohay joined the faculty at the NYU Grossman School of Medicine where he is a Professor of Neurology and Pediatrics (Clinical). In 2021 he became the Director of the Division of Child Neurology. Additionally, Dr. Yohay is the Director of the Comprehensive Neurofibromatosis Center at NYU Langone Health, which is recognized as one of the nation's foremost clinics specializing in neurofibromatosis. His clinical practice is exclusively focused on treating individuals with NF1, NF2, and schwannomatosis. He is involved in the development of best practices for the screening, treatment, and provision of age-appropriate guidance for those affected by neurofibromatosis, as well as the development and education of future NF-focused clinicians.

The MEKtrix

Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Patient Advocate



Renie Moss

Patient Advocate and Caregiver

Renie Moss lives in Alabama with her husband of 24 years, Philip Sr., and two children, Philip Jr. (age 20) and Helen (age 17). Philip Jr. was diagnosed with neurofibromatosis type 1 (NF1) in 2011 when a tumor was discovered in his neck; Helen and Philip Sr. were both diagnosed in 2013. Ms. Moss is an avid advocate for the neurofibromatosis community and the scientific and medical leaders dedicated to finding effective treatments for neurofibromatosis. She is a former chair of the Children's Tumor Foundation (CTF) Volunteer Leadership Council and served as a patient liaison to the Synodos NF1 Research Consortium. She also is a patient representative for Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration (REiNS), helping researchers develop standardized response criteria for determining treatment responses in neurofibromatosis. Locally, Ms. Moss provides patient and caregiver perspectives by serving on the University of Alabama–Birmingham (UAB) NF Clinic Patient Advisory Board and the UAB Genetic Counseling Program's advisory board. She assists in coordinating the annual UAB Neurofibromatosis Symposium and Family Day, connecting with newly diagnosed patients and their families to provide support and encouragement. Professionally, Ms. Moss serves as the operations administrator for the Gregory Fleming James Cystic Fibrosis Research Center at UAB. She holds an undergraduate degree in English and master's degrees in education and public health from UAB..

The MEKtrix

Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Disclosure Declarations

It is the policy of Creative Educational Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. Creative Educational Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Brown reports the following financial relationships:

Advisory Board: Alexion Pharmaceuticals, Inc.; Novocure; and Servier

Consultant: Neurovigil, Inc. (unpaid) and Pasithea Therapeutics

Dr. Chow reports the following financial relationships:

Advisory Board: DayOne Pharmaceuticals and SpringWorks Therapeutics

Speakers Bureau: *American Journal of Managed Care*

Dr. Yohay reports the following financial relationships:

Advisory Board: iNFixion Bioscience

Consultant: Alexion Pharmaceuticals, Inc.

Patient Advocate and Caregiver/Planner

Ms. Moss—no disclosures to report.

Peer Reviewers

Jeffrey Helfand, DO—no disclosures to report.

Andrea Edwards, PA-C—no disclosures to report.

CEC Staff/Planners

Victoria (“Tori”) McClosky, BA, BSN, RN, CBCN—no disclosures to report.

Susan Perry—no disclosures to report.

David Modrak, PhD—no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP—no disclosures to report.

Sandra Caballero, PharmD—no disclosures to report.

Sharon Tordoff—no disclosures to report.

**All identified conflicts of interest have been mitigated.*

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

The MEKtrix

Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty.

Ask Faculty a Question

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

View and Take Notes on Presentation Slides

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to log in to or to create a learner account.



Downloadable Resources

Downloadable resources will be available at ceconcepts.com/themektrixresources.

Engage with Us

Follow us @ceconcepts for announcements about upcoming CME opportunities, health care news, and more!

Thank you for joining us today!

